Bill Alpert
Barron's
Mountain View, CA, United States
Contact Bill
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Bill:
Cologuard Maker Exact Sciences Reports Big Sales and a Surprise Profit
A revenue increase of 28% in the December quarter helps deliver profits ahead of schedule. → Read More
Weed Stocks Are Depressed. Hold Them, Analyst Says.
Cannabis producers in the U.S. and Canada are struggling with weak retail pricing, scarce capital, and persistent U.S. federal restrictions. → Read More
Weight-Loss Drug Shortage Fixed by Year End: Novo Nordisk
The first highly effective weight-loss drug, Wegovy, has been in short supply since it was approved last year. → Read More
A Freight Rail Strike May Still Happen. A Key Date Is Next Month.
Two of a dozen railroad unions have now rejected a September deal that had seemingly averted a strike. → Read More
Illumina's New Gene-Sequencing Products Pressure Challengers
Illumina, a leading maker of gene-sequencing systems, announced faster, cheaper gene-readers Thursday. → Read More
In the SEC's Long Range Plan: Crypto and Machine Learning
The Securities and Exchange Commission is seeking public input on its strategic plan for the next four years. → Read More
Hackers Hijacked Investors’ Accounts to Buy Cannabis and Gaming Shares, Says SEC
The case highlights the need for investors to take care of their online accounts, a top agency official said. → Read More
Illumina Stock Drops as Gene Sequencer's Results Fall Short
The San Diego company slashed its forecast for revenue growth in 2022 to between 4% and 5% from 14% to 16%. → Read More
FDA Advisors Support the First New Gene Therapy in Nearly 5 Years
Recent times have been tough for developers of gene therapies, the formerly-celebrated breakthroughs that address diseases caused by faulty genes. It has been nearly five years since the U.S. Food and Drug Administration asked its outside advisors to weigh in on a gene therapy approval, and stocks in the biotech niche have fallen far out of favor. Thursday and Friday, however, were good days for… → Read More
SEC to Tighten Rules on Funds Labeling Themselves as ESG
SEC Chairman Gary Gensler has been vocal about the commission getting tougher on ESG claims by investment funds. → Read More
The FDA Has Approved Eli Lilly’s Diabetes Drug. But the Most Exciting Market May Be Something Else.
The Food and Drug Administration approved a new diabetes treatment from Eli Lilly on Friday. → Read More
Curaleaf's Weed Sales Were Flat, but Management Is Still Upbeat
The country's largest cannabis chain stuck with a forecast that its sales will increase by 20% in 2022. → Read More
I Tried a New Test That Screens for 50 Kinds of Cancer. What I Learned.
A raft of multicancer blood tests are under development that promise early detection. Our verdict on Grail’s Galleri: An exciting innovation that’s far from routine use. → Read More
8 Experts Explain What the Ukraine War Means for Markets
The fog of this particularly bitter war in Ukraine has crept into global markets. Investors confront a rapidly changing geopolitical scene atop an economy already struggling to cope with inflation, supply-chain woes, and looming interest-rate hikes. No wonder stocks have whipsawed around. To help cut through various aspects of this unfolding crisis—energy, Putin, NATO, and, of course,… → Read More
The Gene-Editing Industry Weighs In on Outlook at J.P. Morgan Conference
Companies like Intellia Therapeutics and Editas Medicine are saying that this year will bring exciting developments. → Read More
SEC Fines J.P. Morgan $125 Million for Doing Business on Personal Phones and Email
More than 100 employees used personal accounts to exchange tens of thousands of messages spanning the broker's business, from trading to investment banking. → Read More
Federal Marijuana Reform Is More Likely Than Ever. The Industry Is Betting on These States.
"We've been focusing our operations around three primary hubs, in Florida, Pennsylvania, and Arizona." Dreamstime Federal legalization of weed got a baby step closer this week, with the introduction of a Republican bill to decriminalize marijuana, but U.S. cannabis operators seem more willing to bet on state reforms. Companies are waiting for recreational sales to start in New York, New Jersey,… → Read More
The Biggest Sports Data Firm Is Now Public. What You Need to Know About Sportsradar.
The Swiss company is another way to bet on sports betting. It had its Nasdaq debut on Tuesday. → Read More
Senate Democrats Propose Taxing Stock Buybacks. What It Means for the Market.
In recent decades, cash-rich companies have used buybacks to reward stockholders and share-incented employees. → Read More
Robinhood Says It Would Challenge a Ban on Payment for Order Flow
"The idea of banning payment for order flow is pretty draconian," Robinhood's legal chief said. → Read More